Publication: Liraglutide Improves Forced Vital Capacity in Individuals With Type 2 Diabetes: Data From the Randomized Crossover LIRALUNG Study.
No Thumbnail Available
Identifiers
Date
2022
Authors
López-Cano, Carolina
Ciudin, Andreea
Sánchez, Enric
Tinahones, Francisco J
Barbé, Ferran
Dalmases, Mireia
García-Ramírez, Marta
Soto, Alfonso
Gaeta, Anna Michela
Pellitero, Silvia
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Metrics
Export
Abstract
To evaluate the effect of liraglutide, a glucagon-like peptide 1 receptor agonist, on pulmonary function and serum levels of surfactant protein D (SP-D) in type 2 diabetes. A double-blind, randomized, crossover, placebo-controlled clinical trial comprising 76 patients with a baseline forced expiratory volume in 1 s
Description
MeSH Terms
Aged
Blood Glucose
Cross-Over Studies
Diabetes Mellitus, Type 2
Double-Blind Method
Female
Glycemic Control
Humans
Liraglutide
Lung
Male
Middle Aged
Pulmonary Surfactant-Associated Protein D
Spain
Vital Capacity
Blood Glucose
Cross-Over Studies
Diabetes Mellitus, Type 2
Double-Blind Method
Female
Glycemic Control
Humans
Liraglutide
Lung
Male
Middle Aged
Pulmonary Surfactant-Associated Protein D
Spain
Vital Capacity